GCP
PRTK

GSA Capital Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

GSA Capital Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-33,571
Closed -$65K – 1975
2022
Q2 		$65K Sell
33,571
-45,877
-58% -$100K 0.01% 1265
2022
Q1 		$236K Buy
79,448
+27,192
+52% +$102K 0.03% 1067
2021
Q4 		$235K Sell
52,256
-27,180
-34% -$129K 0.03% 1111
2021
Q3 		$386K Buy
79,436
+62,192
+361% +$343K 0.04% 858
2021
Q2 		$118K Buy
+17,244
New +$139K 0.01% 1237

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

GSA Capital Partners's PRTK Position: Q3 2022 in Review

GSA Capital Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 33,571 shares — an estimated $65K sold.

GSA Capital Partners first reported a position in PRTK in Q2 2021 and held it in 5 quarters. The position peaked at $386K in Q3 2021. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

  • GSA Capital Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • GSA Capital Partners sold 33,571 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $65K.
  • GSA Capital Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2021 and held it in 5 quarters.
  • GSA Capital Partners's Paratek Pharmaceuticals, Inc. position peaked at $386K in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.